Overview
|
The Pharma and biotech sectors are at a pivotal point in their evolution. The companies are facing significant pressure to change with thinning pipelines, skyrocketing R&D costs, calls for lower prices and a greater regulatory burden, these conditions together with the financial crisis have made the work of creating new drugs harder than ever. Big pharmaceutical companies are being forced to globalize their R&D operations, especially to emerging markets.
Led by China and India, Asia is growing into a drug manufacturing powerhouse and a leading source of drug discovery and high-end innovation during the recent years. Big Pharma companies now rank China as the best location for conducting R&D in Asia, followed by India, Korea and Taiwan, respectively.
|
 |
Looking more closely at China, although the recession has slowed Big Pharma's investment, the country's wide ranging healthcare reforms and changing economic landscape still provide considerable opportunities.
|
| Asia Pharma R&D Leaders 2010 Speakers |
 |
Steve Yang, Ph.D.
Head of Research Asia
Global R&D, Pfizer
|
|
 |
Lily Lee, Ph.D.Senior Vice President and Head of Pharmaceutical R&D Asia Johnson and Johnson
|
|
 |
Hans-Joachim Bohm, Ph.D.
Head of Global Chemistry
Hoffman La-Roche
|
|
 |
Laurent Bertin, M.D.
Vice President, R&D External Innovation
Sanofi-Aventis |
|
 |
Li Chen, Ph.D.
Chief Scientific Officer Roche R&D Center, China |
|
 |
Tony Zhang, Ph.D.
Managing Director and Site Head of China
Eli Lilly Global R&D
|
|
 |
Pierre Desmons, Ph.D.
Vice President, Head of R&D China, GSK Biologicals |
|
 |
Samantha Du, Ph.D.
CEO
Hutchison MediPharma |
|
 |
Richard Wang, Ph.D.
Director of Strategic Alliance and Collaboration for Asia
AstraZeneca Innovation Center China |
|
 |
Daniel Grant, Ph.D.
Head of Strategic Alliances
Pfizer Australia |
|
 |
Yoshiki Nishikawa, Ph.D.
Director, Head of R&D, Kobe Pharma Research Institute
Boehringer Ingelheim |
|
 |
Thomas Evans, M.D.
Head of Translational Sciences
China Novartis Institute of Biomedical Research |
|
 |
Daniel Lee, Ph.D.
Senior Director, Translational Research
GlaxoSmithKline |
|
 |
Jingsong Wang, M.D.
Director of Discovery Medicine & Clinical Pharmacology
Bristol-Myers Squibb |
|
 |
Christopher Hickey, Ph.D.
Country Director of China, U.S. Food and Drug Administration |
|
 |
Junbo Ge, M.D.
Professor & Dean of Department Of Cardiology
Fudan University Zhongshan Hospital
|
|
 |
Jin Li, M.D.
Professor & Dean of Department of Medical Oncology
Fudan University Cancer Hospital |
|
 |
Chuanzhen Lu, M.D.
Professor, Dean of Department of Neurology
Fudan University Huashan Hospital |
|
 |
Su-Yu Chien, RPh, M.S.
President
Taiwan Society of Health - System Pharmacists (TSHP) |
|
 |
Yan Wu, M.D.
Medical and Clinical Development Director
Biogen Idec |
|
 |
Jennifer Hu, Ph.D.
Director, Licensing and External Research, Merck Sharp & Dohme (China) Ltd |
|
 |
Sanjeev K. Chaudhry, Ph.D.
CEO
Super Religare Laboratories Limited |
|
 |
Ajit Nair, Ph.D.
President
SIRO Clinpharm, India |
|
 |
Young Jack Lee, Ph.D.
President
LSK Global Pharma Services, Korea |
|
 |
Jikai Liu, Ph.D.
Director of Kunming Institute of Botany
Chinese Academy of Sciences |
|
 |
Gordon Zong, Ph.D.
Office of Technology Transfer
Shanghai Institute of Biological Sciences, China |
|
 |
Carl Firth, Ph.D.
Head of Asia Pacific Healthcare
Bank of America Merrill Lynch, Hong Kong |
|
 |
Fintan Walton, Ph.D.
Chief Executive Officer and Founder
PharmaVentures UK |
|
 |
Hui Hsing Ma, MBA
General Partner
TVM-Capital |
|
|
|
Program highlights |
- Asian strategies and China focus: managing pharma R&D activities cost and time effectively
- Gain market competitiveness in Asia: deriving maximum value from M&A and licensing deals
- New approaches in pharma R&D: next generation small molecule therapeutics
- Diversifying product pipelines: rethinking about natural products; exploring biologics
- Global experience in clinical trials success: strategies to enhance clinical trial design
- E-clinical trials: leveraging EDC to enhance clinical trials efficiency
- How biotech companies can thrive in the prolonged funding drought
- Realizing personalized medicine through translational research
- Showcase of novel therapeutics for oncology, cardiology, neurology,
inflammation and immunology
|
|
|
Benefits of attending
|
Learn how major innovation breakthrough in world pharma industry will affect your bottom-line. Your most immediate business questions are being tackled by an unrivalled line-up of speakers and panel members.
Key benefits are:
- Discover how to bring drugs to market in a timely and cost effective manner
- Examine the latest case studies employed by leading drug companies
- Network with 200+ industry leaders in drug discovery from all around the world
- Explore funding opportunities to fuel your research and development
- Establish partnership with local organizations to coordinate your operations in Asia
- Benchmark your company's performance against others
- Find partners to conduct clinical trials in Asia
|
|
Participating Companies |
|
|
|
Media Partners
|
| |
 |
|
| |
|
|
